Current Concepts in the Management of Helicobacter Pylori Infection: the Maastricht III Consensus Report

Overview

Journal Gut

Specialty Gastroenterology

Date 2006 Dec 16

PMID 17170018

Citations 552

Authors

P Malfertheiner

F Megraud

C OMorain

F Bazzoli

E El-Omar

D Graham

R Hunt

T Rokkas

N Vakil

E J Kuipers

Affiliations

Soon will be listed here.

Abstract

Background: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000.

Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer.

Results: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat" strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naïve users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility.

Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.

Citing Articles

Spectrum of Upper Gastrointestinal Diseases in Patients Presenting with Dyspepsia-A First Report from Myanmar.

Aye T, Tin T, Aye M, Win T, Kyaw A, Aye K JGH Open. 2025; 9(2):e70121.

PMID: 39974544 PMC: 11835762. DOI: 10.1002/jgh3.70121.

Should Metronidazole Be Included in Second-Line Treatment After Standard Triple Therapy for Helicobacter pylori?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Mori H, Nishizawa T, Morioka K, Kato M, Kanai T Helicobacter. 2025; 30(1):e70010.

PMID: 39868753 PMC: 11771550. DOI: 10.1111/hel.70010.

Correlation between Autoimmune Hashimoto's Thyroiditis and Infection: A Case-Control Study.

Shajari M, Rezaei M, Osmani F, Shafaie E, Tahergorabi Z Middle East J Dig Dis. 2025; 16(4):230-234.

PMID: 39807417 PMC: 11725020. DOI: 10.34172/mejdd.2024.397.

The Aging Stomach: Clinical Implications of Infection in Older Adults-Challenges and Strategies for Improved Management.

Skokowski J, Vashist Y, Girnyi S, Cwalinski T, Mocarski P, Antropoli C Int J Mol Sci. 2024; 25(23).

PMID: 39684537 PMC: 11641014. DOI: 10.3390/ijms252312826.

PCR-based RFLP and ERIC-PCR patterns of Helicobacter pylori strains linked to multidrug resistance in Egypt.

Abdulrahman M, Mansy M, Al-Ghreib K, Johar D, Zaky S Sci Rep. 2024; 14(1):22273.

PMID: 39333134 PMC: 11436738. DOI: 10.1038/s41598-024-72289-z.

References

De Block C, De Leeuw I, Bogers J, Pelckmans P, Ieven M, Van Marck E . Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. Diabetes Care. 2002; 26(1):82-8. DOI: 10.2337/diacare.26.1.82. View

Chan F, To K, Wu J, Yung M, Leung W, Kwok T . Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002; 359(9300):9-13. DOI: 10.1016/s0140-6736(02)07272-0. View

Lehours P, Ruskone-Fourmestraux A, Lavergne A, Cantet F, Megraud F . Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma?. Am J Gastroenterol. 2003; 98(2):291-5. DOI: 10.1111/j.1572-0241.2003.t01-1-07264.x. View

Makristathis A, Barousch W, Pasching E, Binder C, Kuderna C, Apfalter P . Two enzyme immunoassays and PCR for detection of Helicobacter pylori in stool specimens from pediatric patients before and after eradication therapy. J Clin Microbiol. 2000; 38(10):3710-4. PMC: 87461. DOI: 10.1128/JCM.38.10.3710-3714.2000. View

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9. DOI: 10.1056/NEJMoa001999. View

Fischbach W, Dragosics B, Ohmann C, Greiner A, Yang Q, Bohm S . Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology. 2000; 119(5):1191-202. DOI: 10.1053/gast.2000.19579. View

Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M . Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ. 2000; 321(7262):659-64. PMC: 27478. DOI: 10.1136/bmj.321.7262.659. View

Tsutsumi Y, Kanamori H, Yamato H, Ehira N, Kawamura T, Umehara S . Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann Hematol. 2005; 84(12):807-11. DOI: 10.1007/s00277-005-1071-z. View

Cars O, Molstad S, Melander A . Variation in antibiotic use in the European Union. Lancet. 2001; 357(9271):1851-3. DOI: 10.1016/S0140-6736(00)04972-2. View

10.

Gisbert J, Pajares J . Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review. Am J Gastroenterol. 2001; 96(10):2829-38. DOI: 10.1111/j.1572-0241.2001.04235.x. View

11.

Vergara M, Catalan M, Gisbert J, Calvet X . Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005; 21(12):1411-8. DOI: 10.1111/j.1365-2036.2005.02444.x. View

12.

Bourke B, Ceponis P, Chiba N, Czinn S, Ferraro R, Fischbach L . Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol. 2005; 19(7):399-408. View

13.

Fischbach L, van Zanten S, Dickason J . Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther. 2004; 20(10):1071-82. DOI: 10.1111/j.1365-2036.2004.02248.x. View

14.

Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta M, Ferri A . Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000; 14(12):1639-43. DOI: 10.1046/j.1365-2036.2000.00870.x. View

15.

Kuipers E, Nelis G, Klinkenberg-Knol E, Snel P, Goldfain D, Kolkman J . Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2003; 53(1):12-20. PMC: 1773939. DOI: 10.1136/gut.53.1.12. View

16.

Megraud F, Lamouliatte H . Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2003; 17(11):1333-43. DOI: 10.1046/j.1365-2036.2003.01592.x. View

17.

Breuer T, Graham D . Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective?. Am J Gastroenterol. 1999; 94(3):725-9. DOI: 10.1111/j.1572-0241.1999.00943.x. View

18.

Huang J, Zheng G, Sumanac K, Irvine E, Hunt R . Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2004; 125(6):1636-44. DOI: 10.1053/j.gastro.2003.08.033. View

19.

Nozaki K, Shimizu N, Ikehara Y, Inoue M, Tsukamoto T, Inada K . Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci. 2003; 94(3):235-9. PMC: 11160175. DOI: 10.1111/j.1349-7006.2003.tb01426.x. View

20.

Graham D, Opekun A, Yamaoka Y, Osato M, El-Zimaity H . Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther. 2003; 17(2):193-200. DOI: 10.1046/j.1365-2036.2003.01400.x. View